A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)

Phase 2 Terminated 90 enrolled Incyte Corporation

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A phase 2 study to find out if the drug ruxolitinib Phosphate Cream is safe and has beneficial effects in people who have alopecia areata (partial or complete hair loss) when applied to the skin.

Timeline

Start: 2015-11-18
Primary completion: 2017-10-03
Completion: 2017-10-03

Outcome

Outcome not reported

Stopped: “The study was terminated early based on the results of a planned interim analysis.”

Publications

Bayart CB, DeNiro KL, Brichta L, Craiglow BG, Sidbury R. Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata. J Am Acad Dermatol. 2017 Jul;77(1):167-170. doi: 10.1016/j.jaad.2017.03.024. No abstract available.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ruxolitinib	Small molecule	—	Topical